PHTHALIMIDO CEREBLON COMPLEX BINDERS AND TRANSCRIPTION FACTOR DEGRADERS AND METHODS OF USE
Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that may bind to CRBN complex and cause degradation of various proteins e.g., IKZF2 (Helios). Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds to treat diseases and disorders characterized or mediated by the presence of a protein, and hence would benefit from degradation of said protein..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Europäisches Patentamt - (2024) vom: 06. März Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ZHANG TINGHU [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Sonstige Themen: |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2024-03-06, Last update posted on www.tib.eu: 2024-03-19, Last updated: 2024-03-22 |
|---|
| Patentnummer: |
EP4329746 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA001357387 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA001357387 | ||
| 003 | DE-627 | ||
| 005 | 20240322142321.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240322s2024 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA001357387 | ||
| 035 | |a (EPA)EP4329746 | ||
| 035 | |a (EPA)83848845 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ZHANG TINGHU |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a PHTHALIMIDO CEREBLON COMPLEX BINDERS AND TRANSCRIPTION FACTOR DEGRADERS AND METHODS OF USE |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2024-03-06, Last update posted on www.tib.eu: 2024-03-19, Last updated: 2024-03-22 | ||
| 520 | |a Disclosed are compounds and pharmaceutically acceptable salts and stereoisomers thereof that may bind to CRBN complex and cause degradation of various proteins e.g., IKZF2 (Helios). Also disclosed are pharmaceutical compositions containing same, and methods of making and using the compounds to treat diseases and disorders characterized or mediated by the presence of a protein, and hence would benefit from degradation of said protein. | ||
| 650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a JONES LYN HOWARD |4 aut | |
| 700 | 0 | |a LIU HU |4 aut | |
| 700 | 0 | |a CHE JIANWEI |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2024) vom: 06. März |
| 773 | 1 | 8 | |g year:2024 |g day:06 |g month:03 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/83848845/publication/EP4329746A1?q=EP4329746 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 06 |c 03 | ||